Last reviewed · How we verify
Half dose of mRNA-1273
Half dose of mRNA-1273 is a Biologic drug developed by Medigen Vaccine Biologics Corp.. It is currently in Phase 2 development.
At a glance
| Generic name | Half dose of mRNA-1273 |
|---|---|
| Sponsor | Medigen Vaccine Biologics Corp. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Half dose of mRNA-1273 CI brief — competitive landscape report
- Half dose of mRNA-1273 updates RSS · CI watch RSS
- Medigen Vaccine Biologics Corp. portfolio CI
Frequently asked questions about Half dose of mRNA-1273
What is Half dose of mRNA-1273?
Half dose of mRNA-1273 is a Biologic drug developed by Medigen Vaccine Biologics Corp..
Who makes Half dose of mRNA-1273?
Half dose of mRNA-1273 is developed by Medigen Vaccine Biologics Corp. (see full Medigen Vaccine Biologics Corp. pipeline at /company/medigen-vaccine-biologics-corp).
What development phase is Half dose of mRNA-1273 in?
Half dose of mRNA-1273 is in Phase 2.
Related
- Manufacturer: Medigen Vaccine Biologics Corp. — full pipeline
- Compare: Half dose of mRNA-1273 vs similar drugs
- Pricing: Half dose of mRNA-1273 cost, discount & access